|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003379,
umls-concept:C0031327,
umls-concept:C0036043,
umls-concept:C0038760,
umls-concept:C0205314,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0442027,
umls-concept:C0679622,
umls-concept:C0920321,
umls-concept:C0935763,
umls-concept:C1134654,
umls-concept:C1274040,
umls-concept:C1527415
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-5-5
|
|
pubmed:abstractText |
Microtubules play a critical role in many cellular functions, including cell division and mitosis. ABT-751 is a novel sulfonamide antimitotic that binds to the colchicine site on beta-tubulin that leads to a block in the cell cycle at the G2M phase, resulting in cellular apoptosis. ABT-751 was investigated in this phase 1 trial designed to assess its maximum tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BerlinJordanJ,
pubmed-author:CaiYingnaY,
pubmed-author:GordonGary BGB,
pubmed-author:HageyAnneA,
pubmed-author:HandeKenneth RKR,
pubmed-author:KobayashiHiroH,
pubmed-author:LockhartA CraigAC,
pubmed-author:MedinaDianeD,
pubmed-author:MeekKysaK,
pubmed-author:RothenbergMace LML,
pubmed-author:SosmanJeffreyJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2834-40
|
|
pubmed:meshHeading |
pubmed-meshheading:16675578-Administration, Oral,
pubmed-meshheading:16675578-Adult,
pubmed-meshheading:16675578-Aged,
pubmed-meshheading:16675578-Biological Availability,
pubmed-meshheading:16675578-Cell Division,
pubmed-meshheading:16675578-Drug Administration Schedule,
pubmed-meshheading:16675578-Female,
pubmed-meshheading:16675578-Humans,
pubmed-meshheading:16675578-Male,
pubmed-meshheading:16675578-Middle Aged,
pubmed-meshheading:16675578-Neoplasms,
pubmed-meshheading:16675578-Safety,
pubmed-meshheading:16675578-Sulfonamides
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
|
|
pubmed:affiliation |
Vanderbilt/Ingram Cancer Center, Nashville, Tennessee, USA. kenneth.r.hande@vanderbilt.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
